← All trials
NCT06251180
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2029
- First posted
- Feb 9, 2024
- Last posted
- Apr 16, 2024
- Enrollment
- 112
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.